Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2-2025. Patho ...

Accessibility StatementSkip Navigation Financial Results for the Third quarter Ended September 30, 2025 About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them und ...

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, ...

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177495&wire=5&utm_campaign=23or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

公司动态 - Sarepta Therapeutics公司宣布更新其杜氏肌营养不良症基因疗法ELEVIDYS的处方信息 [1] - ELEVIDYS是唯一获批用于治疗杜氏肌营养不良症的基因疗法 [1] - 更新的处方信息包含一项关于急性严重肝损伤和急性肝衰竭风险的加框警告 [1]

监管批准与标签更新 - 美国食品药品监督管理局于周五批准了Sarepta Therapeutics基因疗法Elevidys的新标签[1] - 新标签包含了最严重的安全警告[1] - 新标签限制该疗法仅适用于能够行走的杜氏肌营养不良症患者[1]

Cidara Therapeutics, Inc. ( CDTX ) traded at ~$200 in the pre-market. That was around +90% vs. yesterday’s closing price because the FT published a story that Cidara and Merck & Co., Inc.Bram de Haas brings 15 years of investing experience to the table and has over 5 years of experience managing a Euro hedge fund. He is also a former professional poker player and utilizes his bundle of risk management skills to uncover lucrative investments based on special situations.Analyst’s Disclosure:I/we have no stock ...

RADNOR, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”). On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington’s disease, did not provide sufficient evidence to support uniQure’s Biologics Licen ...

Scholar Rock Holding Corp. (SRRK) stock rose 25.67 percent to $37.79 on Friday after the company posted a wider net loss for the third quarter. The stock opened at $34.76 and traded between $34.25 and $39.50 on the Nasdaq. Shares have moved within a 52-week range of $22.71 to $46.98. Trading volume reached 3.44 million, above the average of 2.52 million.The biotech firm reported a net loss of $102.2 million, including $18.3 million in stock-based compensation, compared to $64.5 million, including $9.7 mill ...